Between 1982 and 1999, 180 consecutive pts with MLCBCLwS were treated in 14 Italian centers. Median FU:79 mo(l-199+). Pts: F102, M 79(ratiol,29), m.age 39 yrs(1470), stage 1/11:114, III/IV:66; bulky mediastinum: 144(80%); BM involvement 4(2%); 28 stage IV pts had disease in the thorax, 27 beyond, 36% had kidney/adrenal glands involved. Results: Therapy pts CR NR/PROGR REL Event Free MACOP/VACOP-B 95 81/94(86)* 13/94(13.8) 6/81(7.4) 73/95(77)** CHOP 43 22/43(51)* 21/43(49) 5/22(22.7) 17/43(40)** IIIGEN+ PBSC 25 20/25 (80) 5/25 (20) 3/20 (15) 16/25 (64) MegaCHOP 9 5/9 (55.5) 4/9 (44.4) 1/5 (20) 4/9 (44.4) BACOD/PROMACE 6 3/6 3/6 3/6 PVEBEC 2 2/2 2/2 *P<0.001; **p<0.001 Considering A.A. I.P.I.,(pts 170), L-LI risk pts were 99,1-IH risk: 71 pts; risk groups were similar in CHOP and VACOP/MACOP-B: the latter had CR rate and EF survival significantly higher than CHOP (L-LI risk pts: CR 89% vs 60% (p=0.002); EPS 79% vs 48%(p=0.003); IH-H risk pts CR 79% vs 28%(p=0.002); EPS 72% vs 21% (p=0.02) Conclusions. The peculiar clinical pattern of MLBCLwS is confirmed. Waiting for the necessary randomized trials, VACOP/MACOP-B was more effective than CHOP, even stratifying the pts with AA IPI.
Mediastinal large B cell lymphoma with sclerosis (MLBCLwS). Therapeutic results in 180 consecutive PTS: MACOP/VACOP-B improves the long term outcome. G
LIBERATI, Anna Marina;
2000
Abstract
Between 1982 and 1999, 180 consecutive pts with MLCBCLwS were treated in 14 Italian centers. Median FU:79 mo(l-199+). Pts: F102, M 79(ratiol,29), m.age 39 yrs(1470), stage 1/11:114, III/IV:66; bulky mediastinum: 144(80%); BM involvement 4(2%); 28 stage IV pts had disease in the thorax, 27 beyond, 36% had kidney/adrenal glands involved. Results: Therapy pts CR NR/PROGR REL Event Free MACOP/VACOP-B 95 81/94(86)* 13/94(13.8) 6/81(7.4) 73/95(77)** CHOP 43 22/43(51)* 21/43(49) 5/22(22.7) 17/43(40)** IIIGEN+ PBSC 25 20/25 (80) 5/25 (20) 3/20 (15) 16/25 (64) MegaCHOP 9 5/9 (55.5) 4/9 (44.4) 1/5 (20) 4/9 (44.4) BACOD/PROMACE 6 3/6 3/6 3/6 PVEBEC 2 2/2 2/2 *P<0.001; **p<0.001 Considering A.A. I.P.I.,(pts 170), L-LI risk pts were 99,1-IH risk: 71 pts; risk groups were similar in CHOP and VACOP/MACOP-B: the latter had CR rate and EF survival significantly higher than CHOP (L-LI risk pts: CR 89% vs 60% (p=0.002); EPS 79% vs 48%(p=0.003); IH-H risk pts CR 79% vs 28%(p=0.002); EPS 72% vs 21% (p=0.02) Conclusions. The peculiar clinical pattern of MLBCLwS is confirmed. Waiting for the necessary randomized trials, VACOP/MACOP-B was more effective than CHOP, even stratifying the pts with AA IPI.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
